QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A10F0BAC488BB1596C5F0CE4F667FB3F;jsessionid=4604EAF85061B7D2112CE838C4F764A6;jsessionid=5C7888C1C796D7E3ECF861FCDD776DA6;jsessionid=FB7B545F5070CABEE2B39869C24668B4;jsessionid=750A7E69A1D597B481F8AE36B0A2EC55;jsessionid=8F28E24925E013490E10D44BF44F3CF4;jsessionid=601689C8FF074AA0833DF9C98623EB3F;jsessionid=290E59D73918A15A54A4983BA0E877AD;jsessionid=CC3FA151FD59CCCF2DA9886C9D91E5E6;jsessionid=D5B7F938FE6F3FA18EBEF3BF7E6DDCF1 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A10F0BAC488BB1596C5F0CE4F667FB3F;jsessionid=4604EAF85061B7D2112CE838C4F764A6;jsessionid=5C7888C1C796D7E3ECF861FCDD776DA6;jsessionid=FB7B545F5070CABEE2B39869C24668B4;jsessionid=750A7E69A1D597B481F8AE36B0A2EC55;jsessionid=8F28E24925E013490E10D44BF44F3CF4;jsessionid=601689C8FF074AA0833DF9C98623EB3F;jsessionid=290E59D73918A15A54A4983BA0E877AD;jsessionid=CC3FA151FD59CCCF2DA9886C9D91E5E6;jsessionid=D5B7F938FE6F3FA18EBEF3BF7E6DDCF1